Clinical trial
EVERREST - Developing a Therapy for Fetal Growth Restriction. A 6 Year Prospective Study to Define the Clinical and Biological Characteristic of Pregnancies Affected by Severe Early Onset Fetal Growth Restriction.
NCT02097667 is registered in ClinicalTrials.gov with University College, London as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- EVERREST - Developing a Therapy for Fetal Growth Restriction. A 6 Year Prospective Study to Define the Clinical and Biological Characteristic of Pregnancies Affected by Severe Early Onset Fetal Growth Restriction.
- Lead sponsor
- University College, London
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 31, 2014
- Completion date
- February 28, 2022
- Enrollment
- 142 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.